- Home
- Equipment
- usa massachusetts
- immune response
Show results for
Refine by
Immune Response Equipment Supplied In Usa Massachusetts
31 equipment items found
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
ImmTOR has significant potential to mitigate unwanted immune responses and induce AAV-specific tolerance to enable redosing of gene therapies. ImmTOR has the potential to administer multiple low doses to achieve therapeutic benefit without risk of overdosing, the ability to treat patients typically excluded from these treatments and is a novel approach to ...
Manufactured by:NanoEnTek, Inc. based inGuro-gu, SOUTH KOREA
The FREND COVID-19 Neutralization Ab is a point-of-care testing (POCT) which can be used to check whether a patient has developed the immune response to SARS-CoV-2 using human serum or plasma ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Selecta Biosciences’ immune tolerance platform, ImmTOR, is designed to give rise to antigen-specific immunity, mitigating unwanted immune ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune ...
by:Kephera Diagnostics, LLC based inFramingham, MASSACHUSETTS (USA)
COVI-QUANT™ is an ELISA test available through Kephera’s CLIA laboratory. Studies show that not all individuals develop a strong immune response after COVID-19 infection or vaccination, especially those who have an immunocompromising condition due to disease, medical treatment, organ transplantation, age, or other causes. These individuals may ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of hepatocytes, and ...
Manufactured by:Ardigen based inKraków, POLAND
Quick solution for effective immune responses in clinical trials; We have created an Artificial Intelligence platform dedicated to being a part of the therapeutic cancer vaccine development. The ArdImmune Vax platform uses sequencing data to generate and prioritize antigen targets for cancer vaccines and T-cell ...
by:Revvity Gene Delivery (formerly SIRION Biotech) based inHamburg, GERMANY
This provides space for flexible vector design with multiple transgenes delivered in one vector. Vaccine development is another popular application for adenoviral vectors. The ability of adenovirus to induce immune response in vivo makes it a great tool for vaccine studies. Revvity’s gene delivery portfolio, where SIRION Biotech’s expertise lives on, ...
by:Aphios Corporation based inWoburn, MASSACHUSETTS (USA)
In order to increase the therapeutic efficiency of such vaccines, adjuvants are used with vaccines to augment the immune response. There are several types of adjuvants with different modes of action. Adjuvants form a depot of antigen at the site of inoculation with slow release of antigens. Adjuvants can improve the performance of vaccines by targeting the ...
Manufactured by:VBI Vaccines Inc. based inCambridge, MASSACHUSETTS (USA)
When properly stimulated, the human immune system is incredibly powerful and has profound potential. Because of their structural similarity to viruses presented in nature, including their particulate nature and repetitive structure, virus-like particles (VLPs) are ideal for stimulating potent immune responses. ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent and selective cytotoxicity. The recognition mechanism is not MHC ...
by:Vaxxas, Inc. based inCambridge, MASSACHUSETTS (USA)
Vaxxas has developed novel technologies that enable vaccines to be applied to the tips of the microprojections under sterile conditions. The HD-MAP delivers the vaccine on its microprojections efficiently to the high density populations of immune cells directly beneath the surface of the skin. The microprojections also trigger natural immuno-cellular alarms that cause vaccine ...
Manufactured by:BTX - Harvard Bioscience, Inc. based inHolliston, MASSACHUSETTS (USA)
The AgilePulse In Vivo System, used for animal immunization, vaccine development, and gene therapy, provides an intra-muscular, intra-dermal, or intra-tumor electroporation solution to produce maximum transfection efficiency. Traditional in vivo nucleic acid delivery systems, such as gene gun delivery, suffer from poor efficiency. The AgilePulse In Vivo System effectively ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
Our lymph node-targeted mKRAS cancer vaccine; Our Amphiphile (AMP)-powered lead candidate, ELI-002, generates a robust immune response against mutant Kristen rat sarcoma (mKRAS), with the potential to offer patients a stronger fight against the most aggressive cancers. Preliminary data have shown that ELI-002 produces a potent mKRAS-specific T-cell ...
by:Cartesian Therapeutics based inGaithersburg, MASSACHUSETTS (USA)
Building upon the proven success of SEL-212, ImmTOR has exciting potential to give rise to antigen-specific immunity across a range of immunogenic compounds when co-administered with biologic therapies like ...
by:Aegle Therapeutics based inWoburn, MASSACHUSETTS (USA)
Advancement of extracellular vesicle therapy to the patient has been hampered by an inability to isolate extracellular vesicles in useful quantities while preserving their structural and functional integrity. EVs derived from MSCs enjoy the same immunosuppressant characteristics of their parent cells. However, when EVs are processed incorrectly, they can trigger an adverse inflammation response ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
MT-303 represents the first candidate in a new therapeutic modality targeting hepatocellular carcinoma (HCC). Liver cancer is a prevalent and challenging cancer with over 850,000 new cases diagnosed globally each year, and the third leading cause of cancer death. The clinical candidate is a first-in-class, GPC3-FcA-LNP, with a strong preclinical profile supporting its advance into this ...
Manufactured by:Isto Biologics based inHopkinton, MASSACHUSETTS (USA)
InQu® is the cell-friendly biosynthetic™ bone graft with proven clinical efficacy leading to faster bone ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
Myeloid is focused on advancing its ATAK CAR monocytes, which are myeloid cells with innate immune receptor-inspired CARs to recognize and kill cancer. Additionally, Myeloid has streamlined manufacturing for its ATAK cell therapy candidates through a rapid, single-day cell process. This method provides significant advantages to the patient, contract development, and manufacturing organizations ...
Manufactured by:Transgene based inIllkirch-Graffenstaden, FRANCE
A new generation of multifunctional oncolytic virus, TG6002 has been designed to combine the mechanism of oncolysis (targeted destruction of the cancer cell) with the production of chemotherapy (5-FU), directly into the ...